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acyl-CoAAdipose triglyceride lipase (ATGL) is required for efﬁcient mobilization of triglyceride (TG) stores in adipose tis-
sue and non-adipose tissues. Therefore, ATGL strongly determines the availability of fatty acids for metabolic
reactions. ATGL activity is regulated by a complex network of lipolytic and anti-lipolytic hormones. These signals
control enzyme expression and the interaction of ATGLwith the regulatory proteins CGI-58 andG0S2. Up to date,
it was unknown whether ATGL activity is also controlled by lipid intermediates generated during lipolysis. Here
we show that ATGL activity is inhibited by long-chain acyl-CoAs in a non-competitive manner, similar as previ-
ously shown for hormone-sensitive lipase (HSL), the rate-limiting enzyme for diglyceride breakdown in adipose
tissue. ATGL activity is only marginally inhibited by medium-chain acyl-CoAs, diglycerides, monoglycerides, and
free fatty acids. Immunoprecipitation assays revealed that acyl-CoAs do not disrupt the protein–protein interac-
tion of ATGL and its co-activator CGI-58. Furthermore, inhibition of ATGL is independent of the presence of CGI-
58 and occurs directly at the N-terminal patatin-like phospholipase domain of the enzyme. In conclusion, our
results suggest that inhibition of the major lipolytic enzymes ATGL and HSL by long-chain acyl-CoAs could rep-
resent an effective feedback mechanism controlling lipolysis and protecting cells from lipotoxic concentrations
of fatty acids and fatty acid-derived lipid metabolites.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Adipose triglyceride lipase (ATGL, also referred to as patatin-like
phospholipase domain containing 2 [PNPLA2] or desnutrin [1]) performs
the ﬁrst step in triglyceride (TG) hydrolysis generating diglyceride (DG)
and free fatty acids (FFAs) [2]. Consequently, the enzyme controls the
availability of FFAs, which may serve as energy substrates, precursors
for other lipids, and lipid signaling molecules. This central function has
a major impact on overall energy metabolism and becomes evident in
fasted ATGL-deﬁcient mice (ATGL-ko). In this mouse model, the lack of
sufﬁcient FFAs for energy conversion promotes the usage of glucose for
energy conversion [3]. As a consequence, short fasting periods ormoder-
ate exercise leads to rapid consumption of glycogen stores. Fasting for
more than 6 h results in hypoglycemia, hypometabolism, and hypother-
mia [3,4].osciences, University of Graz,
1900; fax: +43 316 380 9016.
immermann).
. Open access under CC BY-NC-ND liATGL activity is regulated by a complex network of hormoneswhich
control enzyme expression and the interaction of the enzymewith reg-
ulatory proteins. ATGL is stimulated by the presence of an activator pro-
tein as observed for other TG lipases, such as pancreatic lipase or
lipoprotein lipase. The activator of ATGL is termed comparative gene
identiﬁcation-58 (CGI-58) [or alpha/beta-hydrolase domain containing
5 (ABHD5)] [5]. Currently, the molecular mechanism on how CGI-58
stimulates ATGL activity is unknown [6]. However, loss of either ATGL
or CGI-58 function causes systemic TG accumulation in humans and
mice. This inherited disorder is known as Neutral Lipid Storage Disease
(NLSD) [7]. A second regulatory protein of ATGL is G0/G1 switch gene-2
(G0S2). This protein was originally described to be required to commit
cells to enter the G1 phase of the cell cycle [8]. Recent evidence suggests
that G0S2 speciﬁcally inhibits ATGL activity in rodents and humans
[9,10]. Both G0S2 and CGI-58 have been shown to interact with ATGL.
Furthermore, they are present on lipid droplets and regulated by
metabolic hormones. G0S2 appears to be regulated primarily on the
expression level. The antilipolytic hormone insulin increases G0S2
expression in 3T3-L1 adipocytes, whereas activation of lipolysis by
fasting,β-adrenergic agonists, and tumor necrosis factor-αhas the oppo-
site effect [9,11]. In contrast to G0S2, fasting and β-adrenergic stimula-
tion have minor effects on CGI-58 protein expression in adipose tissue.cense.
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tion with the lipid droplet coating protein perilipin 1 [12]. In non-
activated adipocytes, CGI-58 is bound to perilipin 1 and lipolysis is low.
Upon lipolytic stimulation by β-adrenergic agonists, perilipin 1 gets
phosphorylated by protein kinase A leading to the release of CGI-58
which is now available for ATGL activation. In addition, ATGL activity
is inﬂuenced by other members of lipid droplet coat proteins of the
perilipin (PAT) family. Perilipin 2 has been shown to reduce the lipid
droplet association of ATGL [13]. Recent data also suggest that perilipin
5 interacts with ATGL and inhibits its activity [14–17].
Up to date, it was unknown whether ATGL activity or its interaction
with regulatory proteins is controlled by lipidmetabolites arisingduring
lipolysis. Here we show that ATGL is directly inhibited by long-chain
acyl-CoA via a non-competitive mechanism.
2. Materials and methods
2.1. Materials
Acyl-CoA with various fatty acid chain lengths and triolein were
obtained from Sigma-Aldrich (Taufkirchen, Germany). Radiolabeled
[9,10(N)-3H]triolein was obtained from PerkinElmer Life Sciences and
hexadecyl-CoA was obtained from Avanti Polar Lipids.
2.2. Expression of recombinant proteins
For expression of murine ATGL and CGI-58 in Escherichia coli,
sequences containing the complete open reading frame of murine
ATGL and murine CGI-58 were ampliﬁed from cDNA by PCR using
Phusion™ High Fidelity DNA Polymerase (Finnzymes, Espoo, Finland).
Respective primers were designed to create 5′ and 3′ restriction endo-
nuclease cleavage sites (underlined) for subsequent cloning strategies:
mATGL_fw: 5′-TCGGTACC CATGTTCCCGAGGGAGACCAA-3′
mATGL_rv: 5′-ACCTCGAG TCAGCAAGGCGGGAGGC-3′
mCGI-58_fw: 5′-GGGGATCC CAAAGCGATGGCGGCGG-3′
mCGI-58_rv: 5′-CTGATATC TCAGTCTACTGTGTGGCAGATCTCC-3′.
PCR products were inserted into the target vector pASK-IBA5plus
(IBA, Goettingen, Germany) and transformed into E. coli (strain XL-1
and BL-21 for ATGL and CGI-58, respectively). Protein expression was
induced by adding 200 ng/ml anhydro-tetracycline. Cells were harvest-
ed 3 h after induction. Expression of strep-tagged proteinswas detected
by Western blot analysis using mouse anti-Strep-tag II antibody
(1:5000 dilution; IBA, Goettingen, Germany) as primary antibody and
HRP-linked sheep-anti mouse antibody, (1:10,000; GE Healthcare
Amersham, Buckinghamshire, UK) as secondary antibody.
Transient transfection of Monkey embryonic kidney cells (COS-7,
ATCC CRL-1651) with pcDNA4/HisMax coding for His-tagged ATGL,
HSL, or ß-galactosidase (LacZ) was performed with Metafectene™
(Biontex GmbH) as described [2]. Expression of His-tagged proteins
was detected using anti-His monoclonal antibody (6xHis, BD Biosci-
ences) and a horseradish peroxidase-conjugated anti-mouse antibody
(GE Healthcare) as secondary antibody.
2.3. Preparation of cell and tissue extracts
E. coli and COS-7 cells were disrupted by sonication resuspended in
lysis buffer (0.25 M sucrose, 1 mM dithiothreitol, 1 mM EDTA, 20 μg/
ml leupeptine, 2 μg/ml antipain, 1 μg/ml pepstatin, pH 7.0). Lysates of
E. coliwere centrifuged at 15,000 ×g at 4 °C for 20min. For the prepara-
tion of COS-7 cell extracts, nuclei and unbroken cells were removed by
centrifugation at 1000 ×g at 4 °C for 5min. Supernatants were collected
and used for activity assays. The speciﬁc activity of these lysates ranged
from 100 to 400 nmol/h·mg depending on the expression levels of
recombinant proteins.Mouse gonadal WAT was homogenized in lysis buffer (~1 ml/fat
pad) using an Ultra Turrax Homogenizer (Fisher Scientiﬁc, Waltham,
MA). The homogenate was centrifuged at 20,000 ×g at 4 °C for 1 h.
The interphase was collected and used for activity assays.
2.4. Assay for TG hydrolase activity
The substrate for themeasurement of TG hydrolase activitywas pre-
pared as described previously with minor modiﬁcations [2]. Brieﬂy,
triolein and [9,10-3H]triolein (10 μCi/ml) were emulsiﬁed in the pres-
ence of phosphatidylcholine/phosphatidylinositol using a sonicator
(Virsonic 475, Virtis, Gardiner, NJ) and adjusted to 2.5% BSA (FFA
free). The ﬁnal substrate concentration was 1.67 μmol/ml triolein and
0.15 mg/ml PC/PI (3:1). For kinetic investigations, the TG substrate
was diluted to the indicated concentrations after sonication. Activity
assays were performed using 0.1 ml of cell lysates and 0.1 ml substrate
in a water bath at 37 °C for 20 min. The reaction was terminated by
adding 3.25 ml of methanol/chloroform/heptane (10:9:7) and 1 ml of
0.1 M potassium carbonate, 0.1 M boric acid, pH 10.5. After centrifuga-
tion at 800 ×g for 20 min, the radioactivity in 1 ml of the upper phase
was determined by liquid scintillation counting.
2.5. Protein interaction of ATGL and CGI-58
Cos-7 cells were co-transfected with Flag-tagged CGI-58 and His-
tagged ATGL. After 3 h of binding, FLAG-beads were washed and incu-
bated for 20 min with indicated concentrations of acyl-CoAs at 37 °C.
Subsequently, beads were washed 3-times with lysis buffer, proteins
were eluted by boiling in SDS-containing sample puffer, and probes
were subjected toWestern blot analysis using FLAG- and His-tag specif-
ic antibodies (Monoclonal mouse ANTI-FLAG® M2-Peroxidase (HRP)
antibody, Sigma, A8592; Monoclonal mouse ANTI-HIS antibody, GE
Healthcare, 27-4710-01) and sheep anti-mouse IgG (HRP-linked, GE
Healthcare; NA931) as secondary antibody.
2.6. Protein determinations
Protein concentrations of cell lysates were determined by Bio-Rad
protein assay kit according to manufacturer's instructions (Bio-Rad,
Hercules, CA) using BSA as standard.
2.7. Statistical analysis
Data are presented asmean± S.D. Statistical signiﬁcancewas deter-
mined by the Student's unpaired t-test (two-tailed). Group differences
were considered signiﬁcant for p b 0.05 (*), p b 0.01 (**), and p
b 0.001 (***).
3. Results
3.1. ATGL is inhibited by oleoyl-CoA
Inhibition of ATGL activity by lipid intermediates was ﬁrst investi-
gated in lysates of COS-7 cells expressing His-tagged ATGL and CGI-58.
Lysates containing approximately equimolar concentrations of ATGL
and CGI-58 (Fig. 1A) were incubated with a radiolabeled triolein sub-
strate in the absence (control) or presence of various lipid metabolites.
At a concentration of 50 μM, ATGL activity was almost completely
inhibited in the presence of oleoyl-CoA. In comparison, oleic acid (OA)
had little effect, whereas free CoA, monoolein (MO), and diolein (DO)
did not affect enzyme activity (Fig. 1B). ATGL was also inhibited by a
thioether analog of palmitoyl-CoA (hexadecyl-CoA, Fig. 1B) suggesting
that protein acylation is not required for inactivation.
Addition of oleoyl-CoA led to inactivation of ATGL activity with an
IC50 value of 33 μM (Fig. 1C).
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Fig. 1.ATGL is inhibited by oleoyl-CoA. (A)Western blot analysis of COS-7 cell lysates overexpressing ATGL and CGI-58. (B) TG hydrolase activity of ATGL in presence of 50 μMoleoyl-CoA,
free CoA, free oleic acid, rac-MO, rac-DO and a thioether analog of palmitoyl-CoA (Hexdecyl-CoA). (C) Effect of BSA on oleoyl-CoAmediated inhibition of ATGL activity. The speciﬁc activity
decreased from 3.2 μmol/h·mg to 1.7 μmol/h·mgwhen the BSA concentrationwas reduced from 5% (360 μM) to 0.05%. Data are presented as mean± S.D. from triplicate determinations
and representative for at least three independent experiments.
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presence of excess BSA (360 μM) which harbors high afﬁnity sites for
acyl-CoA [18]. When BSA was omitted from the reaction, we observed
an almost complete inhibition of ATGL activity implicating that the
enzyme requires an FFA acceptor for full activity. In the presence of
low amounts of BSA (3.6 μM), the enzyme retained ~50% of its activity.
Under these conditions, we determined an IC50 value of 21 μM suggest-
ing that BSA moderately interferes with acyl-CoA-mediated enzyme
inhibition (dashed line, Fig. 1C).3.2. ATGL and HSL are inhibited by long-chain acyl-CoAs
HSL has previously been shown to be inhibited by long-chain
acyl-CoAs (LCAs) [19]. To compare the effect of acyl-CoAs of different
chain length on ATGL and HSL activity, we expressed these enzymes
in COS-7 cells and determined TG hydrolase activity in the presence
of various acyl-CoAs. The acyl-CoA-mediated inhibition of TG hydro-
lysis strongly depended on fatty acid length. Both, ATGL and HSL
were inhibited by oleoyl-CoA and palmitoyl-CoA (Fig. 2A). Lauroyl-
CoA inhibited HSL but had no effect on ATGL activity. Acyl-CoA
with shorter chain length did not inhibit either enzyme. Next, we
tested the effect of acyl-CoAs in lysates of mouse white adipose tis-
sue (WAT) where ATGL and HSL are together responsible for more
than 95% of the neutral TG hydrolase activity [20]. In WAT lysates
of wild-type and ATGL-ko mice, TG hydrolase activity was inhibited
by acyl-CoAs exhibiting a fatty acid chain length ≥12 carbon atoms
(Fig. 2B, C). In WAT lysates of HSL-deﬁcient (HSL-ko) mice, where
ATGL represents the major TG lipase, TG hydrolase activity was
inhibited by palmitoyl- and oleoyl-CoA (Fig. 2D) whereas lauroyl-
CoA had no effect. Thus, both ATGL and HSL are inhibited by LCAand only HSL is sensitive to lauroyl-CoA allowing discrimination be-
tween ATGL and HSL activity in biological samples.3.3. Acyl-CoAs interact with the N-terminal domain of ATGL and do not
disrupt the protein interaction of ATGL and CGI-58
Next we investigated whether LCAs inhibit ATGL activity directly by
binding to the enzymeor indirectly by binding to CGI-58 and interfering
with ATGL/CGI-58 interaction. To test if the inhibition is dependent on
CGI-58, we omitted CGI-58 from the reaction. As shown in Fig. 3A,
ATGL was sensitive to LCA-mediated inhibition in the absence of CGI-
58 indicating that LCAs directly interact with the enzyme. To restrict
the binding site of LCAs to N- and C-terminal domains, we used a trun-
cated version of ATGL lacking the C-terminal part of the enzyme
(Q289ter). This truncated ATGL variant comprises the active patatin-
like phospholipase domain and has previously been shown to exhibit
increased lipase activity in comparison to the full-length enzyme [21].
As shown in Fig. 3C, Q289ter was inactivated by oleoyl-CoA which sug-
gests that LCAs interactwith theN-terminal domain of ATGL comprising
the catalytic patatin-like region [22].
To investigate whether LCAs affect the interaction of ATGL and CGI-
58, we performed immunoprecipitation assays using His-tagged CGI-58
and FLAG-tagged ATGL. As expected, we could clearly detect an interac-
tion between these proteins when co-expressed in COS-7 cells (Fig. 3B).
Addition of oleoyl-CoA or lauroyl-CoA had no effect suggesting that acyl-
CoAs do not disrupt the interaction of ATGL and its activator protein.
To exclude that other cofactors are required for LCA-mediated inhi-
bition of ATGL, we switched to a heterologous expression system and
expressed Strep-tagged ATGL and CGI-58 in E. coli. As shown in
Fig. 3C, ATGLwas active in E. coli lysates and inactivated by the addition
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Fig. 2. ATGL and HSL are speciﬁcally inhibited by long-chain acyl-CoAs. (A) TG hydrolase activity of COS-7 cell lysates overexpressing ATGL/CGI-58 or HSL in presence of acyl-CoAs with
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suggest that LCA directly inhibit ATGL.
3.4. Long-chain acyl-CoAs inhibit ATGL in a non-competitive manner
To get insight into the mechanism of inhibition, we performed
inhibitor kinetic studies. For this purpose, we used E. coli lysates con-
taining ATGL and CGI-58. First, we tested whether we can apply
Michaelis–Menten kinetics. As shown in Fig. 4A, saturation kinetics
revealed an almost linear increase in enzyme activity up to 800 μMsub-
strate. Furthermore, time course experiments demonstrated that the re-
action was linear for at least 30 min in the absence and presence of
oleoyl-CoA suggesting that steady-state conditions are achieved
(Fig. 4B). Inhibitor kinetics were performed using different substrate
and inhibitor concentrations in a concentration range of 200–800 μM
triolein and 0, 10, 20, and 40 μM oleoyl-CoA, respectively. As shown in
Fig. 4C, inhibition of ATGL by oleoyl-CoA was almost independent of
the substrate concentration. Accordingly, Lineweaver–Burk analysis
revealed that oleoyl-CoA reduced Vmax but did not affect Km demon-
strating that acyl-CoA-mediated inhibition occurs in a non-competitive
manner (Fig. 4D). Using nonlinear regression analysis (GraphPad Prism
5, GraphPad Inc.) and amodel formixed inhibition kinetics we calculated
a Ki of 19 ± 5 μM.
4. Discussion
Generally, FFAs have to be activated to acyl-CoAs for further
metabolization such as β-oxidation, synthesis of complex lipids, or pro-
tein acylation. It is well known that acyl-CoAs are not only short-lived
metabolites, but directly regulate central enzymes in energy and lipidmetabolism including mitochondrial adenine nucleotide translocase,
acetyl-CoA carboxylase, pyruvate dehydrogenase, andphosphofructoki-
nase [23]. Furthermore, LCAs regulate the activity of different protein
kinase C subtypes and are directly or indirectly involved in the control
of gene expression, ion ﬂuxes, and membrane trafﬁcking [23].
Previous studies demonstrated that LCAs inhibit tissue TG lipase
activity [24,25] and HSL by non-competitive inhibition [19,26]. Here
we show that LCA also target ATGL and inhibit the enzyme in a non-
competitive manner. Our data indicate that differences exist with
respect to the efﬁcacy of acyl-CoA species, since HSL but not ATGL is
inhibited by lauroyl-CoA. We assume that this observation does not
have physiological relevance, since lauric acid is a minor component
of cellular lipids (~0.3% in WAT; [27]). Conversely, both enzymes are
inhibited by acyl-CoA esteriﬁedwith the highly abundant fatty acid spe-
cies palmitic acid and oleic acid. Since inactivation of ATGL and HSL
almost completely abolishes WAT fatty acid release [20], our data sug-
gest that LCA control the activity of the major lipolytic enzymes. It is
important to note that FFA metabolism is causally linked to metabolic
disease. Increased circulating FFAs, as observed in obesity, can cause
FFA overload of non-adipose tissues resulting in ectopic TG accumula-
tion which is associated with impaired metabolic functions of these tis-
sues, insulin resistance, and inﬂammation. These changes are not
caused by the increase of the inert TG storage pool. It is believed that
elevated cellular FFA levels promote the synthesis of lipotoxic metabo-
lites such as ceramides, acyl-CoAs, and diacylglycerol [28–30]. FFA over-
load may result from increased lipolysis and impaired β-oxidation [31]
and both processes can elevate cellular acyl-CoA concentrations.
Notably, acyl-CoA concentrations are increased in tissues of insulin
resistant subjects and the correlation betweenmuscle acyl-CoA content
and insulin resistance is stronger than that between muscle TG stores
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inhibition of lipolysis could represent a principle feedback mechanism
reducing FFA concentrations and promoting the storage of inert TG.
It is interesting to note that the increase in circulating FFA levels in
obese patients is modest in comparison to the enormous expansion of
WAT [33]. This suggests thatWATmaintains its ability to control lipoly-
sis despite hypertrophy and hyperplasia. Actually, FFA release per kilo-
gram fat mass is reduced in obesity [33] and elevated plasma FFA
levels may result from increased adipose mass. Acyl-CoA-mediated
inhibition of lipolysis may be one mechanism preventing TG degrada-
tion in obese subjects and this could be speciﬁcally important in the in-
sulin resistant state, since insulin is considered as the major suppressor
of lipolysis [34].
Cellular LCA concentrations have been reported to be in the range of
5–160 μM and strongly depend on the metabolic state and tissue-type
[35]. Accordingly, the IC50 values determined for ATGL inhibition are
clearly within the physiological range. However, it has to be considered
that LCA are primarily bound to acyl-CoA binding protein (ACBP) acting
as acyl-CoA transporter [36]. Additionally, liver fatty acid binding pro-
tein can bind LCA with high afﬁnity [37]. Because of the high cellular
concentrations of LCA binding proteins, it is assumed that LCAs are pres-
ent in their free form in very small amounts [36]. Currently, it is unclear
how ACBP-bound LCA affect ATGL activity. Yet, it has been shown that
ACBP-bound LCA are available for metabolic or regulatory processes
such as beta-oxidation, synthesis of lipids, and signal transduction
[35]. Furthermore, addition of ACBP promotes the inhibitory effect of
palmitoyl-CoA on partially puriﬁed HSL [25]. It was also shown that
LCA stimulate non-HSL lipase activity in pancreatic islets and this stim-
ulatory effect was blocked by the addition of ACBP [25]. Thus, we
assume that free and ACBP-bound LCAs can affect ATGL activity.Obviously, extensive studies are required to determine the role of
ACBPs in lipolysis. In this respect, it is interesting to note that ACBP-
deﬁcient mice show a complex metabolic phenotype. These mice go
through a crisis with overall weakness at weaning [38] indicating that
ACBP is important for metabolic adaptionwhichmight also include reg-
ulation of lipolysis.
The mechanism of LCA-mediated ATGL inhibition appears to be
independent of CGI-58, since inactivation of the enzyme was also
observed in the absence of its co-activator protein and acyl-CoA did
not disrupt the protein interaction of ATGL and CGI-58. LCAs were
able to inhibit full-length ATGL and the truncated variant Q289ter lack-
ing the C-terminal domain indicating that they bind to the N-terminal
patatin-like phospholipase domain (PNPLA). Furthermore, ATGL was
sensitive to LCA inhibition in a heterologous expression system exclud-
ing an important contribution of other co-factors. Notably, several
PNPLA proteins have been shown to possess acyl-CoA dependent
acyltransferase activity such as adiponutrin [39], GS2 [40], and yeast
lipases Tgl3p, Tgl4p, and Tgl5p [41,42]. To our knowledge ATGL does
not exhibit this activity, but it is reasonable to assume that ATGL has a
yet uncharacterized conserved LCA-binding motif with regulatory
function.5. Conclusion
LCAs can directly inhibit ATGL in a non-competitivemanner. Consid-
ering that LCAs also inhibit HSL, LCA-mediated inhibition of lipolytic
enzymes could represent an effective cellular mechanism controlling
lipolysis. Inhibition of lipases could be important in adipose and non-
adipose tissues, avoid FFA-mediated lipotoxicity, and promote TG
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ACBP acyl-CoA binding protein
ATGL adipose triglyceride lipase
ATGL-ko ATGL-deﬁcient
CGI-58 comparative gene identiﬁcation-58
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DO diolein
FFA free fatty acid
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HSL-ko HSL-deﬁcient
LCA long-chain acyl-CoA
MGL monoglyceride lipase
MO monoolein
OA oleic acid
PNPLA patatin-like phospholipase domain containing protein
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